Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease
(2024) In Digestive Diseases and Sciences 69(6). p.2175-2183- Abstract
Background: Real-world data on starting intravenous (IV) vedolizumab (VDZ) and transitioning to subcutaneous (SC) treatment in inflammatory bowel disease (IBD) are scarce. Aims: To assess treatment outcomes of patients with IBD starting IV VDZ and switching to SC VDZ in routine clinical care. Methods: Adult patients with IBD switching from IV to SC VDZ treatment between 1 March 2020 and 31 December 2021 were identified from the Swedish IBD quality register. The primary outcome was SC VDZ persistence. Secondary outcomes included clinical remission, changes in quality of life (QoL) according to EuroQual 5-Dimensions 5-Levels (EQ-5D-5L) and the Short-Health Scale (SHS) and inflammatory markers, including faecal Calprotectin (FCP). Results:... (More)
Background: Real-world data on starting intravenous (IV) vedolizumab (VDZ) and transitioning to subcutaneous (SC) treatment in inflammatory bowel disease (IBD) are scarce. Aims: To assess treatment outcomes of patients with IBD starting IV VDZ and switching to SC VDZ in routine clinical care. Methods: Adult patients with IBD switching from IV to SC VDZ treatment between 1 March 2020 and 31 December 2021 were identified from the Swedish IBD quality register. The primary outcome was SC VDZ persistence. Secondary outcomes included clinical remission, changes in quality of life (QoL) according to EuroQual 5-Dimensions 5-Levels (EQ-5D-5L) and the Short-Health Scale (SHS) and inflammatory markers, including faecal Calprotectin (FCP). Results: Altogether, 406 patients with IBD (Crohn's disease, n = 181; ulcerative colitis, n = 225) were identified. After a median follow-up of 30 months from starting IV VDZ treatment, the persistence rates were 98%(178/181) in Crohn's disease and 94% (211/225) in ulcerative colitis. Most patients (84%) transitioned during maintenance therapy, and the median follow-up from switch to SC VDZ was 10 months. Compared to baseline, statistically significant improvements were observed in all domains of the SHS, EQ-5D index value and visual analogue scale. Median (interquartile range) FCP concentrations (μg/g) decreased from 459 (185–1001) to 65 (26–227) in Crohn's disease (n = 45; p < 0.001) and from 646 (152–1450) to 49 (20–275) in ulcerative colitis (n = 58; p < 0.001). Conclusion: Initiating IV VDZ and switching to SC treatment was associated with high persistence rates and improvements in measures of QoL and FCP. These findings are reassuring for patients who start IV VDZ and switch to SC VDZ. Graphical Abstract: (Figure presented.)
(Less)
- author
- Lamichhane, N. ; Melas, N. ; Bergqvist, V. LU ; Ekholm, N. P. ; Olén, O. ; Ludvigsson, J. F. ; Hjortswang, H. ; Marsal, J. LU ; Eriksson, C. and Halfvarson, J.
- author collaboration
- organization
- publishing date
- 2024
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Inflammatory bowel disease, Observational study, Real-world data, Vedolizumab
- in
- Digestive Diseases and Sciences
- volume
- 69
- issue
- 6
- pages
- 2175 - 2183
- publisher
- Springer
- external identifiers
-
- scopus:85190691369
- pmid:38637457
- ISSN
- 0163-2116
- DOI
- 10.1007/s10620-024-08422-9
- language
- English
- LU publication?
- yes
- id
- fa61422e-abd4-4024-bc93-03efefd615a5
- date added to LUP
- 2024-05-14 15:42:50
- date last changed
- 2024-12-11 14:26:32
@article{fa61422e-abd4-4024-bc93-03efefd615a5,
abstract = {{<p>Background: Real-world data on starting intravenous (IV) vedolizumab (VDZ) and transitioning to subcutaneous (SC) treatment in inflammatory bowel disease (IBD) are scarce. Aims: To assess treatment outcomes of patients with IBD starting IV VDZ and switching to SC VDZ in routine clinical care. Methods: Adult patients with IBD switching from IV to SC VDZ treatment between 1 March 2020 and 31 December 2021 were identified from the Swedish IBD quality register. The primary outcome was SC VDZ persistence. Secondary outcomes included clinical remission, changes in quality of life (QoL) according to EuroQual 5-Dimensions 5-Levels (EQ-5D-5L) and the Short-Health Scale (SHS) and inflammatory markers, including faecal Calprotectin (FCP). Results: Altogether, 406 patients with IBD (Crohn's disease, n = 181; ulcerative colitis, n = 225) were identified. After a median follow-up of 30 months from starting IV VDZ treatment, the persistence rates were 98%(178/181) in Crohn's disease and 94% (211/225) in ulcerative colitis. Most patients (84%) transitioned during maintenance therapy, and the median follow-up from switch to SC VDZ was 10 months. Compared to baseline, statistically significant improvements were observed in all domains of the SHS, EQ-5D index value and visual analogue scale. Median (interquartile range) FCP concentrations (μg/g) decreased from 459 (185–1001) to 65 (26–227) in Crohn's disease (n = 45; p < 0.001) and from 646 (152–1450) to 49 (20–275) in ulcerative colitis (n = 58; p < 0.001). Conclusion: Initiating IV VDZ and switching to SC treatment was associated with high persistence rates and improvements in measures of QoL and FCP. These findings are reassuring for patients who start IV VDZ and switch to SC VDZ. Graphical Abstract: (Figure presented.)</p>}},
author = {{Lamichhane, N. and Melas, N. and Bergqvist, V. and Ekholm, N. P. and Olén, O. and Ludvigsson, J. F. and Hjortswang, H. and Marsal, J. and Eriksson, C. and Halfvarson, J.}},
issn = {{0163-2116}},
keywords = {{Inflammatory bowel disease; Observational study; Real-world data; Vedolizumab}},
language = {{eng}},
number = {{6}},
pages = {{2175--2183}},
publisher = {{Springer}},
series = {{Digestive Diseases and Sciences}},
title = {{Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease}},
url = {{http://dx.doi.org/10.1007/s10620-024-08422-9}},
doi = {{10.1007/s10620-024-08422-9}},
volume = {{69}},
year = {{2024}},
}